Prothena Corporation Public Limited Company last reported quarterly results on Aug 6, 2026, for Q2 FY2026 (the quarter ended Jun 30, 2026): revenue of $1.0 million (-77.1% year over year) and diluted EPS of -$0.36. It usually reports 37–50 days after a quarter ends. Based on that pattern, the next release is estimated for around Nov 5, 2026.
Results for Q3 FY2026, the quarter ending around Sep 30, 2026. Expected on a Thursday. Based on last year's release for the same quarter on Nov 6, 2025. The company has not filed these results with the SEC yet. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 37–50 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Aug 6, 2026
37 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
1
-77.1%
|
-19
+85.2%
|
-0.36
+84.6%
|
|
May 7, 2026
37 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
51
+1706.4%
|
33
+154.4%
|
0.60
+153.6%
|
|
Feb 19, 2026
50 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
0
-99.0%
|
-22
+62.7%
|
-0.40
+62.8%
|
|
Nov 6, 2025
37 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
2
+149.0%
|
-37
+38.1%
|
-0.68
+38.2%
|
|
Aug 4, 2025
35 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
4
-96.7%
|
-126
-288.0%
|
-2.34
-291.8%
|
|
May 8, 2025
38 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
3
+5556.0%
|
-60
+16.7%
|
-1.12
+16.4%
|
|
Feb 20, 2025
51 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
2
+571.8%
|
-58
+14.1%
|
-1.08
+14.3%
|
|
Nov 12, 2024
43 days after quarter end
|
Q3 FY2024
ended Sep 30, 2024
|
1
-98.9%
|
-59
-369.3%
|
-1.10
-389.5%
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- PRTA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Ireland
- Headquarters
- Dublin 2, Ireland
- SEC filer status
- Accelerated filer
- SEC CIK
- 1559053
- Former names
- Prothena Corp plc (until May 22, 2020); Neotope Corp Ltd (until Oct 1, 2012)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.